ClinicalTrials.gg
Active, not recruitingNCT06576271Updated Nov 12, 2026

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

A Phase 1 interventional study of GSK4527363 and Placebo matching GSK4527363 in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Active, not recruiting at 23 sites in 6 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
14th of 36
143 · median 81
Started
2024
with 2 others
Phase 1
7 of 36
none open now
Registered
34th of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 14th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 1, and was the 34th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Belimumab
  • First time in human study
  • GSK4527363
  • Healthy participants
  • Immunogenicity
  • Pharmacokinetics
  • Systemic lupus erythematosus
  • Interstitial lung disease
  • Connective tissue disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part A and Part C (Healthy Participants):

  • Participant must be 18 to 55 years of age inclusive, at the time of signing the form
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (vital signs and 12-lead )
  • Part C only: Be of Japanese (Cohort C1) or Chinese (Cohort C2) ancestry i. Born in Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2); and ii. Descendent of 2 ethnic Japanese (Cohort C1) or Chinese (Cohort C2) parents and 4 ethnic grandparents; and iii. Have lived outside Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2) for less than 10 years at the time of screening
  • Body weight greater than or equals to (>=) 45 kilograms (kg)
  • (BMI) within the range 18-32 kilograms per square meter (kg/m\^2) (inclusive)
  • Male or female of non-

For Part B (SLE participants):

  • 18 to 65 years of age inclusive, at the time of signing the informed consent form
  • Documented clinical diagnosis of SLE according to the (European alliance of associations of rheumatology [EULAR]/ American College of Rheumatology [ACR] SLE classification criteria)
  • Body weight >= 45 kg
  • BMI within the range 18-32 kg/m\^2 (inclusive)
  • Male or female
  • Capable of giving signed informed consent For Part D (CTD-ILD Participants)
  • Participants must be 18 to 65 years of age, at the time of signing the informed consent form
  • Documented clinical diagnosis of specific Connective Tissue Diseases in accordance with internationally recognised classification criteria
  • Documented clinical diagnosis of interstitial lung disease (ILD) as determined by historical High-resolution computed tomography (HRCT)
  • Participants must be on a stable dose of therapy to manage ILD and/or underlying connective tissue disease (CTD)
  • Body weight >= 45 kg
  • BMI within the range 18-32 kg/m\^2 (inclusive)
  • Male or female
  • Capable of giving signed informed consent

Exclusion criteria

Exclusion criteria:

For Part A and Part C (Healthy Participants):

  • History or presence or cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders
  • A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug
  • Any acute infection (including upper respiratory tract infections and urinary tract infections) which has not fully resolved within four weeks before dosing
  • Symptomatic herpes zoster within 3 months prior to screening
  • Have a history of , or a strong family history of malignancies related to
  • multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions
  • Abnormal blood pressure
  • Evidence of active or latent Tuberculosis (TB)
  • (ALT) >=1.1* (ULN)
  • Total >1.0*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >=1.5*ULN as long as direct bilirubin is less than or equal to (\<=)1.5*ULN
  • Presence of surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
  • Positive antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention
  • Positive (HIV) antibody test at screening
  • Prior medical history of anaphylaxis
  • corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec)
  • (s) within 30 days before the dosing day or plans to receive such vaccines during the study

For Part B (SLE participants):

  • Any acute, severe lupus related flare during the Screening Period that needs immediate treatment
  • Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk
  • Have an acute or chronic infection requiring management as follows:

    i. Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria ii. A serious infection requiring treatment with antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed

  • Evidence of active or latent TB
  • Confirmed Progressive Multifocal Leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms
  • ALT >2*ULN
  • Total bilirubin >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is >1.5*ULN
  • Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
  • History or positive test at Screening for HIV
  • QTcF >450 msec
  • Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, Cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix that have been resected with no evidence of disease for 3 years
  • Live or live-attenuated vaccine(s) within 30 days prior to Screening

For Part D Participants:

  • A diagnosis of: ILD other than CTD-ILD and/or SLE
  • FVC \<= 45% predicted at Screening Pulmonary arterial hypertension, as determined by the Investigator, prior to Day 1
  • Major surgery (including joint surgery) within 3 months prior to Screening or planned during the duration of the study
  • Previous or planned major organ transplant (e.g. heart, lung, kidney, liver) or bone marrow transplant (e.g. stem cell transplant)
  • Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to CTD-ILD (i.e., cardiovascular, metabolic, hematologic, GI, hepatic, renal, neurological, psychiatric, malignancy, or infectious diseases) which, in the opinion of the PI, could confound the results of the clinical study or put the participant at undue risk
  • Have an acute or chronic infection including requiring management
  • Evidence of active or latent TB
  • Confirmed PML or unexplained new-onset or deteriorating neurologic signs and symptoms
  • ALT >2*ULN
  • Total bilirubin >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is >1.5*ULN
  • Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
  • History or positive test at Screening for HIV
  • Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, CIN or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years
  • Live or live-attenuated vaccine(s) within 30 days prior to Screening or plans to receive such vaccines during the Screening period or during the clinical study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Part A: Healthy participants receiving GSK4527363

    Drug: GSK4527363

  • Placebo comparator
    Part A: Healthy participants receiving placebo matching GSK4527363

    Drug: Placebo matching GSK4527363

  • Experimental
    Part A: Healthy participants receiving belimumab

    Drug: Belimumab

  • Experimental
    Part B: Participants with SLE receiving GSK4527363

    Drug: GSK4527363

  • Experimental
    Part B: Participants with SLE receiving belimumab

    Drug: Belimumab

  • Experimental
    Part C: Healthy Japanese participants receiving GSK4527363

    Drug: GSK4527363

  • Placebo comparator
    Part C: Healthy Japanese participants receiving placebo matching GSK4527363

    Drug: Placebo matching GSK4527363

  • Experimental
    Part C: Healthy Chinese participants receiving GSK4527363

    Drug: GSK4527363

  • Placebo comparator
    Part C: Healthy Chinese participants receiving placebo matching GSK4527363

    Drug: Placebo matching GSK4527363

  • Experimental
    Part D: Participants with CTD-ILD receiving GSK4527363

    Drug: GSK4527363

Interventions

  • DrugGSK4527363

    GSK4527363 will be administered to participants.

  • DrugPlacebo matching GSK4527363

    Placebo matching GSK4527363 will be administered to participants.

  • Belimumab will be administered to participants.

06

What researchers measure

Primary outcomes

  1. Parts A and C: Number of Participants with Non-serious Adverse Events and Serious Adverse Events

    Time frame: Up to Week 52

  2. Parts B and D: Number of Participants with Non-serious Adverse Events and Serious Adverse Events

    Time frame: Up to Week 68

  3. Parts A and C: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) Findings

    Time frame: Up to Week 52

  4. Parts B and D: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) Findings

    Time frame: Up to Week 68

  5. Parts A and C: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. A suicidal ideation score will be calculated based on the maximum suicidal ideation category ranging from 1 to 5. Higher score indicates more suicidal ideation. A clinically important change in the C-SSRS is defined as a total score \>0.

    Time frame: Up to Week 52

  6. Parts B, and D: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. A suicidal ideation score will be calculated based on the maximum suicidal ideation category ranging from 1 to 5. Higher score indicates more suicidal ideation. A clinically important change in the C-SSRS is defined as a total score \>0.

    Time frame: Up to Week 68

Secondary outcomes

  1. Parts A and C: Area Under the Concentration-time Curve to the Last Quantifiable Concentration (AUC[0-t]) of GSK4527363

    Time frame: Up to Week 52

  2. Parts A and C: Area Under the Concentration-time Curve to Infinity (AUC[0-inf]) of GSK4527363

    Time frame: Up to Week 52

  3. Parts A and C: Maximum Plasma Concentration (Cmax) of GSK4527363

    Time frame: Up to Week 52

  4. Parts A and C: Apparent Terminal Phase Half-life (t1/2) of GSK4527363

    Time frame: Up to Week 52

  5. Parts A and C: Number of Participants with Anti-drug Antibodies (ADAs) Against GSK4527363

    Time frame: Up to Week 52

  6. Parts B and D: Number of Participants with Anti-drug Antibodies (ADAs) Against GSK4527363

    Time frame: Up to Week 68

  7. Parts A, B and C: Titers of ADAs Against GSK4527363

    Time frame: Up to Week 52

  8. Parts A and C: Percentage change from Baseline in cytokine levels

    Time frame: Baseline (Day 1) and up to Week 52

  9. Parts B and D: Percentage change from Baseline in cytokine levels

    Time frame: Baseline (Day 1) and up to Week 68

  10. Part B and D: Area Under the Concentration-time Curve of GSK4527363

    Time frame: Up to Week 12

  11. Part B and D: Maximum Plasma Concentration of GSK4527363

    Time frame: Up to Week 12

  12. Part B and D: Concentration at the end of the First Dosing Interval of GSK4527363

    Time frame: Up to Week 12

07

Study locations

23 sites
  • GSK Investigational Site
    Las Vegas, Nevada 89154, United States
  • GSK Investigational Site
    Columbus, Ohio 44109, United States
  • GSK Investigational Site
    Buenos Aires, C1280AEB, Argentina
  • GSK Investigational Site
    Rosario, S2002, Argentina
  • GSK Investigational Site
    San Juan Bautista, B1888AAE, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, T4000IHE, Argentina
  • GSK Investigational Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • GSK Investigational Site
    Juiz de Fora, 36010-570, Brazil
  • GSK Investigational Site
    Porto Alegre, 90480000, Brazil
  • GSK Investigational Site
    Salvador, 40050-410, Brazil
  • GSK Investigational Site
    Bydgoszcz, 85-065, Poland
  • GSK Investigational Site
    Poznan, 61-848, Poland
  • GSK Investigational Site
    Warsaw, 02-665, Poland
  • GSK Investigational Site
    Wroclaw, 50-556, Poland
  • GSK Investigational Site
    Pamplona Iruna, Navarre 31008, Spain
  • GSK Investigational Site
    Barcelona, 08916, Spain
  • GSK Investigational Site
    Bilbao, 48013, Spain
  • GSK Investigational Site
    Sabadell Barcelona, 08208, Spain
  • GSK Investigational Site
    Valladolid, 47012, Spain
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
  • GSK Investigational Site
    Liverpool, L7 8YE, United Kingdom
  • GSK Investigational Site
    London, SW3 6HP, United Kingdom
  • GSK Investigational Site
    Middlesex, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Feb 2028, 40 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 40 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2028 → Feb 2028 and completion Jan 2028 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
Sep 2, 2024
Primary completionEst.
Feb 1, 2028was Jan 2028
CompletionEst.
Feb 1, 2028was Jan 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Sites
1 site added, 6 sites removed
Show site
  • GSK Investigational Site · Pamplona Iruna, Spain
Show 6 removed
  • GSK Investigational Site · Scottsdale, United States
  • GSK Investigational Site · Aurora, United States
  • GSK Investigational Site · Oklahoma City, United States
  • GSK Investigational Site · Dallas, United States
  • GSK Investigational Site · Krakow, Poland
  • GSK Investigational Site · Pamplona, Spain
Nov 12, 2026
Primary completion
Jan 11, 2028→Feb 1, 2028
Nov 12, 2026
Study completion
Jan 11, 2028→Feb 1, 2028
Nov 12, 2026
Enrollment
142 (estimated)→143 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    1 site added, 6 sites removed
    Show site
    • GSK Investigational Site · Pamplona Iruna, Spain
    Show 6 removed
    • GSK Investigational Site · Scottsdale, United States
    • GSK Investigational Site · Aurora, United States
    • GSK Investigational Site · Oklahoma City, United States
    • GSK Investigational Site · Dallas, United States
    • GSK Investigational Site · Krakow, Poland
    • GSK Investigational Site · Pamplona, Spain
    Primary completion Jan 11, 2028→Feb 1, 2028
    Study completion Jan 11, 2028→Feb 1, 2028
    Enrollment 142 (estimated)→143 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06576271
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Sep 2, 2024
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion